Advances in Chagas disease drug development: 2009-2010

Current Opinion in Infectious Diseases

Volumn 23, Issue 6, 2010, Pages 609-616

  Buckner, Frederick S ^a   Navabi, Nazlee ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chagas disease; drug development; Trypanosoma cruzi

Indexed keywords

5 NITRO 2 FURYL DERIVATIVE; ANTIPROTOZOAL AGENT; ARISTOLOCHIA CYMBIFERA EXTRACT; BENZNIDAZOLE; CUBEBIN; DB 766; DIBENZYLBUTYROLACTONE; HINOKININ; K 777; KUSUNOKININ; LIGNAN; MILTEFOSINE; NIFURTIMOX; NIFURTIMOX ANALOG; NONAZOLE 14ALPHA DEMETHYLASE INHIBITOR; NONPEPTIDIC CRUZAIN INHIBITOR; PAFURAMIDINE; PENTAMIDINE; PLANT EXTRACT; POSACONAZOLE; RAVUCONAZOLE; RUTHENIUM COMPLEX; STEROL 14ALPHA DEMETHYLASE; TIPIFARNIB; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; AMASTIGOTE; ANTIPROTOZOAL ACTIVITY; ARISTOLOCHIA; ARISTOLOCHIA CYMBIFERA; CARDIOTOXICITY; CHAGAS DISEASE; CLINICAL TRIAL; DRUG HALF LIFE; DRUG TARGETING; GENOTOXICITY; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; LEISHMANIASIS; NONHUMAN; PARASITEMIA; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

ANIMALS; ANTIFUNGAL AGENTS; BIOLOGICAL PRODUCTS; CHAGAS DISEASE; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEGLECTED DISEASES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 78349274397     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283402956     Document Type: Review

References (62)

1. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. J Am Med Assoc 2007; 298:2171-2181.
2. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375: 1388-1402.
3. Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010; 115:55-68.
4. Marin-Neto JA, Rassi A Jr, Avezum A, et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 2009; 104 (1 Suppl):319-324.
5. Clayton J. Chagas disease: pushing through the pipeline. Nature 2010; 465:S12-S15.
6. Ribeiro I, Sevcsik AM, Alves F, et al. New, improved treatments for Chagas disease: from the R&D pipeline to the patients. PLoS Negl Trop Dis 2009; 3:e484.
7. Harth G, Andrews N, Mills AA, et al. Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Mol Biochem Parasitol 1993; 58:17-24.
8. McKerrow JH, Doyle PS, Engel JC, et al. Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz 2009; 104 (1 Suppl):263-269.
9. Brak K, Kerr ID, Barrett KT, et al. Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy. J Med Chem 2010; 53:1763-1773.
10. Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 2009; 104 (1 Suppl):311-318.
11. Olivieri BP, Molina JT, de Castro SL, et al. A comparative study of posaco-nazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. Int J Antimicrob Agents 2010; 36:79-83.
12. Kraus JM, Verlinde CL, Karimi M, et al. Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem 2009; 52:1639-1647.
13. Suryadevara PK, Olepu S, Lockman JW, et al. Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem 2009; 52:3703-3715.
14. Doyle PS, Chen CK, Johnston JB, et al. A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. Antimicrob Agents Chemother 2010; 54:2480-2488.
15. Berman JJ. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol 2008; 4:1209-1216.
16. Luna KP, Hernandez IP, Rueda CM, et al. In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole. Biomedica 2009; 29:448-455.
17. Croft SL, Snowdon D, Yardley V. The activities of four anticanceralkyllysopho-spholipids against Leishmania donovani, Trypanosoma cruzi, and Trypanosoma brucei. J Antimicrob Chemother 1996; 38:1041-1047.
18. Freitas RF, Prokopczyk IM, Zottis A, et al. Discovery of novel Trypanosoma cruzi glyceraldehyde-3-phosphate dehydrogenase inhibitors. Bioorg Med Chem 2009; 17:2476-2482.
19. Schormann N, Velu SE, Murugesan S, et al. Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase. Bioorg Med Chem 2010; 18:4056-4066.
20. Huang CH, Gabelli SB, Oldfield E, Amzel LM. Binding of nitrogen-containing bisphosphonates (N-BPs) to the Trypanosoma cruzi farnesyl diphosphate synthase homodimer. Proteins 2010; 78:888-899.
21. Berman J. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 2003; 16:397-401.
22. Maudlin I.African trypanosomiasis. Ann Trop Med Parasitol 2006; 100:679-701.
23. Soeiro MN, de Castro SL, de Souza EM, et al. Diamidine activity against trypanosomes: the state of the art. Curr Mol Pharmacol 2008; 1:151-161.
24. Batista DG, Batista MM, de Oliveira GM, et al. Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment. Antimicrob Agents Chemother 2010; 54:2940-2952.
25. Pacheco MG, da Silva CF, de Souza EM, et al. Trypanosoma cruzi: activity of heterocyclic cationic molecules in vitro. Exp Parasitol 2009; 123:73-80.
26. Batista DG, Pacheco MG, Kumar A, et al. Biological, ultrastructural effect and subcellular localization of aromatic diamidines in Trypanosoma cruzi. Para-sitology 2010; 137:251-259.
27. Nyunt MM, Hendrix CW, Bakshi RP, et al. Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2009; 80:528-535.
28. Yeramian PD, Castagnini LA, Allen JA, et al. Efficacy and safety of DB289, a new oral drug for treatment of Pneumocystis carinii pneumonia (PCP) in AIDS patients. Presented at the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting, September 14-17, 2003, Chicago, IL; 2010.
29. Cabrera E, Murguiondo MG, Arias MG, et al. 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies. Eur J Med Chem 2009; 44:3909-3914.
30. Wilkinson SR, Taylor MC, Horn D, et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA 2008; 105:5022-5027.
31. Sanchez-Delgado RA, Anzellotti A. Met al complexes as chemotherapeutic agents against tropical diseases: trypanosomiasis, malaria and leishmaniasis. Mini Rev Med Chem 2004; 4:23-30.
32. Nogueira Silva JJ, Pavanelli WR, Gutierrez FR, et al. Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy. J Med Chem 2008; 51:4104-4114.
33. Guedes PM, Oliveira FS, Gutierrez FR, et al. Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas' disease. Br J Pharmacol 2010; 160:270-282.
34. Silva JJ, Guedes PM, Zottis A, et al. Novel ruthenium complexes as potential drugs for Chagas's disease: enzyme inhibition and in vitro/in vivo trypanocidal activity. Br J Pharmacol 2010; 160:260-269.
35. Silva JJ, Pavanelli WR, Pereira JC, et al. Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors. Antimicrob Agents Chemother 2009; 53:4414-4421.
36. Matsuo AL, Silva LS, Torrecilhas AC, et al. In vitro and in vivo trypanocidal effects of the cyclopalladated 7a compound: a drug candidate for Chagas' disease treatment. Antimicrob Agents Chemother 2010; 54:3318-3325.
37. Vieites M, Smircich P, Guggeri L, et al. Synthesis and characterization of a pyridine-2-thiol N-oxide gold(I) complex with potent antiproliferative effect against Trypanosoma cruzi and Leishmania sp. insight into its mechanism of action. J Inorg Biochem 2009; 103:1300-1306.
38. Rodriguez J, Aran VJ, Boiani L, et al. New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and mechanism of action studies. Bioorg Med Chem 2009; 17:8186-8196.
39. Bollini M, Casal JJ, Alvarez DE, et al. New potent imidazoisoquinolinone derivatives as anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships. Bioorg Med Chem 2009; 17:1437-1444.
40. Boiani M, Boiani L, Merlino A, et al. Second generation of 2H-benzimidazole 1,3-dioxide derivatives as antitrypanosomatid agents: synthesis, biological evaluation, and mode of action studies. Eur J Med Chem 2009; 44:4426-4433.
41. Gerpe A, Boiani L, Hernandez P, et al. Naftifine-analogues as anti-Trypano-soma cruzi agents. Eur J Med Chem 2010; 45:2154-2164.
42. Gigante F, Kaiser M, Brun R, Gilbert IH. SAR studies on azasterols as potential antitrypanosomal and antileishmanial agents. Bioorg Med Chem 2009; 17:5950-5961.
43. Pardo Andreu GL, Inada NM, Pellon RF, et al. In vitro effect of a newcinnamic acid derivative against the epimastigote form of Trypanosoma cruzi. Arznei-mittelforschung 2009; 59:207-211.
44. Magdaleno A, Ahn IY, Paes LS, Silber AM. Actions of a proline analogue, L-thiazolidine-4-carboxylic acid (T4C), on Trypanosoma cruzi. PLoS ONE 2009; 4:e4534.
45. Lorente SO, Rodrigues JC, Jimenez JC, et al. Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob Agents Chemother 2004; 48:2937-2950.
46. Ennes-Vidal V, Menna-Barreto RF, Santos AL, et al. Effects of the calpain inhibitor MDL28170 on the clinically relevant forms of Trypanosoma cruzi in vitro. J Antimicrob Chemother 2010; 65:1395-1398.
47. Saraiva J, Vega C, Rolon M, et al. In vitro and in vivo activity of lignan lactones derivatives against Trypanosoma cruzi. Parasitol Res 2007; 100:791-795.
48. Esperandim VR, da Silva FD, Saraiva J, et al. Reduction of parasitism tissue by treatment of mice chronically infected with Trypanosoma cruzi with lignano lactones. Parasitol Res 2010; 107:525-530.
49. Sartorelli P, Salomone CC, Quero RJ, et al. Antitrypanosomal activity of a diterpene and lignans isolated from Aristolochia cymbifera. Planta Med 2010 [Epub ahead of print].
50. Saraiva J, Lira AA, Esperandim VR, et al. (-)-Hinokinin-loaded poly(D,-lactide-co-glycolide) microparticles for Chagas disease. Parasitol Res 2010; 106:703-708.
51. Menna-Barreto RF, Goncalves RL, Costa EM, et al. The effects on Trypano-soma cruzi of novel synthetic naphthoquinones are mediated by mitochondrial dysfunction. Free Radic Biol Med 2009; 47:644-653.
52. Tonin LT, Panice MR, Nakamura CV, et al. Antitrypanosomal and antileish-manial activities of novel N-alkyl-(1-phenylsubstituted-beta- carboline)-3-car-boxamides. Biomed Pharmacother 2010; 64:386-389.
53. da Silva EN Jr, Guimaraes TT, Menna-Barreto RF, et al. The evaluation of quinonoid compounds against Trypanosoma cruzi: synthesis of imidazolic anthraquinones, nor-beta-lapachone derivatives and beta-lapachone-based 1,2,3-triazoles. Bioorg Med Chem 2010; 18:3224-3230.
54. Ferreira DS, Esperandim VR, Toldo MP, et al. Trypanocidal activity and acute toxicity assessment of triterpene acids. Parasitol Res 2010; 106:985-989.
55. Cabral MM, Barbosa-Filho JM, Maia GL, et al. Neolignans from plants in northeastern Brazil (Lauraceae) with activity against Trypanosoma cruzi. Exp Parasitol 2010; 124:319-324.
56. Buckner FS, Verlinde CLMJ, La Flamme AC, Van Voorhis WC. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing b-galactosidase. Antimicrob Agents Chemother 1996; 40:2592-2597.
57. Bettiol E, Samanovic M, Murkin AS, et al. Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosomacruzi by chemical library screening. PLoS Negl Trop Dis 2009; 3:e384.
58. Molina J, Martins-Filho O, Brener Z, et al. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosup-pressed murine hosts. Antimicrob Agents Chemother 2000; 44:150-155.
59. Pinazo MJ, Espinosa G, Gallego M, et al. Successful treatment with posa-conazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 2010; 82:583-587.
60. Diniz LF, Caldas IS, Guedes PM, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother 2010; 54:2979-2986.
61. Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis 2009; 3:e488.
62. Romanha AJ, Castro SL, Soeiro MN, et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz 2010; 105:233-238.